Latest Content

The OVERLORD-MS trial finds rituximab matches ocrelizumab in relapsing multiple sclerosis, with similar MRI control, relapses, and safety.

Experts at the Washington, DC, Pop Health Roundtable discussed delays in ILD diagnosis, multidisciplinary care, antifibrotic therapy, and insurance barriers.

All from July, these 5 novel therapeutics each claimed a “first” in their category.

Constrained optimization empirically derived social risk weights that gave equal influence to subgroup performance by dual eligibility and disability in overall contract scores.

Coverage of our peer-reviewed research and news reporting in the health care and mainstream press.

This study links county-level social vulnerability to variation in Medicare Advantage prior authorization policies.

Accelerated approval is granted to RP1 plus nivolumab for advanced melanoma after PD-1 failure, following nail-biting FDA approval process.

Phase 3 SOLARIS found high-dose vitamin D3 added to standard chemotherapy did not significantly improve progression-free survival in metastatic CRC.

A new AHA scientific statement defines pediatric cardiogenic shock and proposes a 5-stage classification to guide diagnosis, monitoring, and escalation of care.